AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 810767 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 810767 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline theophyllinate
Number of subjects: 0
Study 810767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 0
Study 810767 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 810767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31466474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, naproxen, diclofenac, ibuprofen, and selective cyclooxygenase 2 inhibitors such as celecoxib.
Number of subjects: 0
Study 30840633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide 0.8 ng/kg
Number of subjects: 60
Study 30840633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide 0.6 ng/kg
Number of subjects: 60
Study 30840633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30840633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Number of subjects: 60
Study 28827237 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngopharyngeal endoscopic esthesiometer and rangefinder (LPEER)
Number of subjects: 0
Study 28827237 — intervention group
Group type: EXPERIMENTAL
Intervention: LPEER
Number of subjects: 0
Study 26000301 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX; 60% VO2peak)
Number of subjects: 17
Study 26000301 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (CON)
Number of subjects: 17
Study 23406026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation plus medical therapy
Number of subjects: 251
Study 23406026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation
Number of subjects: 251
Study 23406026 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 251
Study 22828986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle manoeuvre (IPM)
Number of subjects: 126
Study 22828986 — intervention group
Group type: COMPARATOR
Intervention: No Pringle manoeuvre (NPM)
Number of subjects: 126
Study 18842671 — intervention group
Group type: EXPERIMENTAL
Intervention: High bicarbonate concentration (35 mmol/l)
Number of subjects: 21
Study 18842671 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium concentration (1.50 mmol/l)
Number of subjects: 21
Study 17502632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (9-month multilevel intervention)
Number of subjects: 314
Study 17502632 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 15206638 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent and staffed residential settings
Number of subjects: 0
Study 11591981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 14 mmHg
Number of subjects: 93
Study 11591981 — intervention group
Group type: COMPARATOR
Intervention: Gasless technique
Number of subjects: 93
Study 11591981 — intervention group
Group type: COMPARATOR
Intervention: Pneumoperitoneum at 10 mmHg
Number of subjects: 93
Study 11591981 — intervention group
Group type: COMPARATOR
Intervention: Non-hepatobiliary laparoscopic procedures
Number of subjects: 93
Study 9751938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 0
Study 7999486 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine 1 mg min‐1 (group E1: n = 10)
Number of subjects: 29
Study 7999486 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine 2 mg min‐1 (group E2: n = 9)
Number of subjects: 29
Study 7999486 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylephrine 10 micrograms min‐1 (group P: n = 10)
Number of subjects: 29
Study 7999486 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylephrine 10 micrograms min‐1 with bolus doses of 20 micrograms
Number of subjects: 29
Study 7999486 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine 1 or 2 mg min‐1 with bolus doses of 6 mg
Number of subjects: 29
Study 3288946 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose trimethoprim-sulfamethoxazole
Number of subjects: 132
Study 3288946 — intervention group
Group type: COMPARATOR
Intervention: 3-day regimen of trimethoprim-sulfamethoxazole
Number of subjects: 132
Study 3288946 — intervention group
Group type: COMPARATOR
Intervention: 7-day regimen of trimethoprim-sulfamethoxazole
Number of subjects: 132
Study 30962423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration after extinction training (n = 25)
Number of subjects: 50
Study 30962423 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration after extinction training (n = 25)
Number of subjects: 50
Study 29197407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (LTV) ventilation: 5 breaths/minute with a tidal volume of 3 mL/kg and positive end-expiratory pressure of 5 cmH2O
Number of subjects: 1500
Study 29197407 — intervention group
Group type: COMPARATOR
Intervention: No ventilation (noV) during CPB
Number of subjects: 1500
Study 29197407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (LTV) ventilation
Number of subjects: 1500
Study 25873548 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical voice
Number of subjects: 93
Study 25873548 — intervention group
Group type: COMPARATOR
Intervention: Dysphonic voice
Number of subjects: 93
Study 23701521 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedles + iontophoresis
Number of subjects: 12
Study 23701521 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis alone
Number of subjects: 12
Study 21788625 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy germ pasta (one serving/day for 8 weeks)
Number of subjects: 0
Study 21788625 — intervention group
Group type: COMPARATOR
Intervention: Conventional pasta (one serving/day for 8 weeks)
Number of subjects: 0
Study 19105577 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (orthographically similar)
Number of subjects: 0
Study 19105577 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic association task (experimental condition)
Number of subjects: 0
Study 19105577 — intervention group
Group type: EXPERIMENTAL
Intervention: Vowel counting task (experimental condition)
Number of subjects: 0
Study 19105577 — intervention group
Group type: COMPARATOR
Intervention: Control condition (orthographically dissimilar)
Number of subjects: 0
Study 16472987 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clindamycin
Number of subjects: 150
Study 16472987 — intervention group
Group type: COMPARATOR
Intervention: 2 g phenethicillin
Number of subjects: 150
Study 16472987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (clindamycin and phenethicillin)
Number of subjects: 150
Study 12882677 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrowand technique under arthroscope
Number of subjects: 72
Study 12882677 — intervention group
Group type: COMPARATOR
Intervention: Knee arthroscope (control group)
Number of subjects: 72
Study 10728957 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb‐IIIa inhibitor orbofiban
Number of subjects: 0
Study 10728957 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9194208 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucillamine
Number of subjects: 46
Study 9194208 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 46
Study 1539881 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine solutions prepared seven days, one day, and just before use
Number of subjects: 24
Study 1539881 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 24
Study 3895175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 50
Study 3895175 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (ampicillin and chloramphenicol)
Number of subjects: 50
Study 3895175 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study 31382653 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum dietary diversity (MDD) consumption (≥4/8 items)
Number of subjects: 305
Study 31382653 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of animal source foods
Number of subjects: 305
Study 31382653 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of vegetables/fruits
Number of subjects: 305
Study 31382653 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of processed foods
Number of subjects: 305
Study 29633302 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in females
Number of subjects: 48
Study 29633302 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in males
Number of subjects: 48
Study 29633302 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in females (pivotal study)
Number of subjects: 48
Study 29633302 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in males (pivotal study)
Number of subjects: 48
Study 29633302 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test/reference ratio in pilot study
Number of subjects: 48
Study 29633302 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test/reference ratio in pivotal study
Number of subjects: 48
Study 27369111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 1815
Study 27369111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg every 4 weeks (Rq4)
Number of subjects: 1815
Study 27369111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks (2q8)
Number of subjects: 1815
Study 25171023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 148
Study 25171023 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 148
Study 22487001 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 8500 UI once daily for 10 days followed by placebo for 20 days (group A)
Number of subjects: 664
Study 22487001 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 8500 UI once daily for 10 days followed by 6400 UI once daily for 20 days (group B)
Number of subjects: 664
Study 22487001 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 4250 UI once daily for 30 days (group C)
Number of subjects: 664
Study 22487001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group B vs. group A
Number of subjects: 664
Study 22487001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group B vs. group C
Number of subjects: 664
Study 22487001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group C vs. group A
Number of subjects: 664
Study 22487001 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 664
Study 22487001 — intervention group
Group type: EXPERIMENTAL
Intervention: No major hemorrhages occurred.
Number of subjects: 664
Study 20517641 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (0.5 mg/kg/day)
Number of subjects: 34
Study 20517641 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (0.3-1 mg/kg/day)
Number of subjects: 34
Study 20517641 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 34
Study 20517641 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 34
Study 17613851 — intervention group
Group type: EXPERIMENTAL
Intervention: Free examination
Number of subjects: 484
Study 17613851 — intervention group
Group type: COMPARATOR
Intervention: Standard (pay) examination
Number of subjects: 484
Study 15127961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 224
Study 15127961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 32 mg
Number of subjects: 224
Study 15127961 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (10 microg/kg or 1 mg)
Number of subjects: 224
Study 11961610 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 51
Study 11961610 — intervention group
Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 51
Study 9447512 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing (IMN)
Number of subjects: 168
Study 9447512 — intervention group
Group type: COMPARATOR
Intervention: Half-pin external fixators (EF)
Number of subjects: 168
Study 7646913 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcapsular orchiectomy plus oral hydrocortisone and bromocriptine (arm 3)
Number of subjects: 30
Study 7646913 — intervention group
Group type: COMPARATOR
Intervention: Subcapsular orchiectomy alone (arm 1)
Number of subjects: 30
Study 7646913 — intervention group
Group type: COMPARATOR
Intervention: Subcapsular orchiectomy plus flutamide (arm 2)
Number of subjects: 30
Study 2676529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled-release morphine (30 mg)
Number of subjects: 10
Study 2676529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 349776 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste 'Silka' with circulation-stimulation additives
Number of subjects: 0
Study 31129665 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar hysteroscopic surgery using a mixture of 2.7% sorbitol and 0.54% mannitol (HSMP group)
Number of subjects: 54
Study 31129665 — intervention group
Group type: COMPARATOR
Intervention: Bipolar hysteroscopic surgery using 0.9% isotonic saline (HSBP group)
Number of subjects: 54
Study 31129665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HSMP and HSBP)
Number of subjects: 54
Study 28829792 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise for 12 weeks
Number of subjects: 23
Study 28829792 — intervention group
Group type: COMPARATOR
Intervention: Non-exercised control group
Number of subjects: 23
Study 25483694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent Staphylococcus aureus glycoconjugated vaccine (2 doses)
Number of subjects: 3359
Study 25483694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3359
Study 23400901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 76
Study 23400901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimator
Number of subjects: 76
Study 21860342 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose MDMA (1.0 mg/kg)
Number of subjects: 29
Study 21860342 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose MDMA (1.6 mg/kg)
Number of subjects: 29
Study 21860342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 21860342 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA detection
Number of subjects: 29
Study 21860342 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA detection
Number of subjects: 29
Study 21860342 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA detection window
Number of subjects: 29
Study 21860342 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA detection window
Number of subjects: 29
Study 21860342 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA positive rates
Number of subjects: 29
Study 19246703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 101
Study 19246703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 16100299 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine
Number of subjects: 26
Study 16100299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11833048 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g sucrose with a moderate fat load
Number of subjects: 20
Study 11833048 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose with a moderate fat load
Number of subjects: 20
Study 11833048 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk group
Number of subjects: 20
Study 11833048 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 10084100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram kg-1 clonidine
Number of subjects: 36
Study 10084100 — intervention group
Group type: COMPARATOR
Intervention: 30 micrograms kg-1 morphine
Number of subjects: 36
Study 8977623 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanol vapor exposure at 200 ppm for 4 hours
Number of subjects: 26
Study 8977623 — intervention group
Group type: COMPARATOR
Intervention: Water vapor exposure (control)
Number of subjects: 26
Study 2149995 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine
Number of subjects: 72
Study 2149995 — intervention group
Group type: COMPARATOR
Intervention: mitomycin
Number of subjects: 72
Study 10246465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet delivery method
Number of subjects: 50
Study 10246465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet and nurse visit delivery method
Number of subjects: 50
Study 10246465 — intervention group
Group type: COMPARATOR
Intervention: Nurse visit delivery method
Number of subjects: 50
Study 10246465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative information)
Number of subjects: 50
Study 30359062 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining restricted future time perspective
Number of subjects: 0
Study 30359062 — intervention group
Group type: COMPARATOR
Intervention: Imagining expansive future time perspective
Number of subjects: 0
Study 30359062 — intervention group
Group type: COMPARATOR
Intervention: No instructions
Number of subjects: 0
Study 29029896 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (5·36 mg orally twice daily) for 90 days
Number of subjects: 50
Study 29029896 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 50
Study 29029896 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (5·36 mg orally twice daily) for 60 days
Number of subjects: 50
Study 25545446 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum light (BSL) phototherapy
Number of subjects: 40
Study 25545446 — intervention group
Group type: COMPARATOR
Intervention: Blue LED phototherapy
Number of subjects: 40
Study 23415431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnut-enriched diet (4 weeks; hazelnut contributing 18%-20% of total daily energy intake)
Number of subjects: 21
Study 23415431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnut-enriched diet
Number of subjects: 21
Study 23415431 — intervention group
Group type: COMPARATOR
Intervention: Control diet I (4 weeks)
Number of subjects: 21
Study 23415431 — intervention group
Group type: COMPARATOR
Intervention: Control diet II (4 weeks)
Number of subjects: 21
Study 21240901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 15 μg daily
Number of subjects: 0
Study 21240901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19594841 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin-A (BoNT-A)
Number of subjects: 47
Study 19594841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17523268 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary drainage through the cystic duct
Number of subjects: 40
Study 17523268 — intervention group
Group type: COMPARATOR
Intervention: Biliary drainage through the other procedure (not specified)
Number of subjects: 40
Study 15355147 — intervention group
Group type: EXPERIMENTAL
Intervention: High school students
Number of subjects: 0
Study 15355147 — intervention group
Group type: EXPERIMENTAL
Intervention: American participants
Number of subjects: 0
Study 15355147 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese participants
Number of subjects: 0
Study 15355147 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not report being reminded of the source tale
Number of subjects: 0
Study 15355147 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity of solution tool
Number of subjects: 0
Study 15355147 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity of goal object
Number of subjects: 0
Study 11685343 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIDS with respiratory rate (RR) of 14 min(‐1)
Number of subjects: 7
Study 11685343 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIDS with respiratory rate (RR) of 20 min(‐1)
Number of subjects: 7
Study 11685343 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIDS
Number of subjects: 7
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 mL daily)
Number of subjects: 180
Study 9481031 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (10 mL daily)
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma leptin concentration
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma leptin concentration for female fetuses
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma leptin concentration for male fetuses
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration at birth (umbilical cord plasma)
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration at 4 weeks
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration at 14 weeks
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin levels at 4 and 14 weeks
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration increase from 4 to 14 weeks
Number of subjects: 180
Study 9481031 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentration in umbilical cord plasma
Number of subjects: 180
Study 7817456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and megadose multivitamins in combination with intravesical BCG
Number of subjects: 0
Study 7817456 — intervention group
Group type: EXPERIMENTAL
Intervention: KLH (keyhole limpet hemocyanin)
Number of subjects: 0